Clinical value of inflammatory urinary biomarkers in overt diabetic nephropathy: A prospective study

Diabetes Research and Clinical Practice

Volumn 101, Issue 3, 2013, Pages 333-340

  Verhave, Jacobien C ^a   Bouchard, Josée ^a   Goupil, Rémi ^a   Pichette, Vincent ^b   Brachemi, Soumeya ^c   Madore, François ^a   Troyanov, Stéphan ^a  

^a HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^b MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Diabetic nephropathy; MCP 1; Proteinuria; Rate of renal function decline; TGF 1; Urinary biomarkers

Indexed keywords

ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; CREATININE; HEMOGLOBIN A1C; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; ORAL ANTIDIABETIC AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

AGED; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG USE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROTEINURIA; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

DIABETIC NEPHROPATHY; MCP-1; PROTEINURIA; RATE OF RENAL FUNCTION DECLINE; TGF-Β1; URINARY BIOMARKERS;

BIOLOGICAL MARKERS; CHEMOKINE CCL2; DIABETIC NEPHROPATHIES; GLOMERULAR FILTRATION RATE; HUMANS; INFLAMMATION; INTERLEUKIN-6; INTERLEUKIN-8; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSPECTIVE STUDIES; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84885376285     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2013.07.006     Document Type: Article

References (41)

1. Information CIfH Canadian Organ Replacement Register Annual Report: Treatment of End-Stage Organ Failure in Canada, 2001 to 2010 2011, CIHI, Ottawa, Ont.
2. Berhane A.M., Weil E.J., Knowler W.C., Nelson R.G., Hanson R.L. Albuminuria and estimated glomerular filtration rate as predictors of diabetic end-stage renal disease and death. Clin J Am Soc Nephrol 2011, 6:2444-2451.
3. Molitch M.E., Steffes M., Sun W., Rutledge B., Cleary P., de Boer I.H., et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care 2010, 33:1536-1543.
4. Kramer H.J., Nguyen Q.D., Curhan G., Hsu C.Y. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 2003, 289:3273-3277.
5. Perkins B.A., Ficociello L.H., Silva K.H., Finkelstein D.M., Warram J.H., Krolewski A.S. Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003, 348:2285-2293.
6. Schrijvers B.F., De Vriese A.S., Flyvbjerg A. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev 2004, 25:971-1010.
7. Wada J., Makino H. Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci (Lond) 2013, 124:139-152.
8. Hellemons M.E., Kerschbaum J., Bakker S.J., Neuwirt H., Mayer B., Mayer G., et al. Validity of biomarkers predicting onset or progression of nephropathy in patients with Type 2 diabetes: a systematic review. Diabet Med 2012, 29:567-577.
9. Navarro-Gonzalez J.F., Mora-Fernandez C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 2008, 19:433-442.
10. Gilbert R.E., Akdeniz A., Allen T.J., Jerums G. Urinary transforming growth factor-beta in patients with diabetic nephropathy: implications for the pathogenesis of tubulointerstitial pathology. Nephrol Dial Transplant 2001, 16:2442-2443.
11. Titan S.M., Vieira J.M., Dominguez W.V., Moreira S.R., Pereira A.B., Barros R.T., et al. Urinary MCP-1 and RBP: independent predictors of renal outcome in macroalbuminuric diabetic nephropathy. J Diabet Complications 2012, 26:546-553.
12. Wada T., Furuichi K., Sakai N., Iwata Y., Yoshimoto K., Shimizu M., et al. Up-regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of human diabetic nephropathy. Kidney Int 2000, 58:1492-1499.
13. American Diabetes A Diagnosis and classification of diabetes mellitus. Diabetes Care 2004, 27(Suppl. 1):S5-S10.
14. Gross J.L., de Azevedo M.J., Silveiro S.P., Canani L.H., Caramori M.L., Zelmanovitz T. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005, 28:164-176.
15. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation, Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130:461-470.
16. Holmquist L., Brostrom H. A simple Beckman DU accessory for location of proteins separated by isoelectric focusing in granulated gel layers: isolation of human serum very low density apolipoproteins C-II and C-III-1. J Biochem Biophys Methods 1979, 1:117-127.
17. Pencina M.J., D'Agostino R.B., D'Agostino R.B., Vasan R.S. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008, 27:157-172.
18. Perkins B.A., Ficociello L.H., Roshan B., Warram J.H., Krolewski A.S. In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney Int 2010, 77:57-64.
19. Retnakaran R., Cull C.A., Thorne K.I., Adler A.I., Holman R.R., Group U.S. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 2006, 55:1832-1839.
20. Lim A.K., Tesch G.H. Inflammation in diabetic nephropathy. Mediators Inflamm 2012, 2012:146-154.
21. Furuta T., Saito T., Ootaka T., Soma J., Obara K., Abe K., et al. The role of macrophages in diabetic glomerulosclerosis. Am J Kidney Dis 1993, 21:480-485.
22. Ziyadeh F.N., Hoffman B.B., Han D.C., Iglesias-De La Cruz M.C., Hong S.W., Isono M. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 2000, 97:8015-8020.
23. Chow F.Y., Nikolic-Paterson D.J., Ma F.Y., Ozols E., Rollins B.J., Tesch G.H. Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice. Diabetologia 2007, 50:471-480.
24. Chow F.Y., Nikolic-Paterson D.J., Ozols E., Atkins R.C., Rollin B.J., Tesch G.H. Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int 2006, 69:73-80.
25. Suzuki D., Miyazaki M., Naka R., Koji T., Yagame M., Jinde K., et al. In situ hybridization of interleukin 6 in diabetic nephropathy. Diabetes 1995, 44:1233-1238.
26. Qi W., Chen X., Polhill T.S., Sumual S., Twigg S., Gilbert R.E., et al. TGF-beta1 induces IL-8 and MCP-1 through a connective tissue growth factor-independent pathway. Am J Physiol Renal Physiol 2006, 290:703-709.
27. Hovind P., Tarnow L., Rossing P., Teerlink T., Stehouwer C.D., Emeis J.J., et al. Progression of diabetic nephropathy: role of plasma homocysteine and plasminogen activator inhibitor-1. Am J Kidney Dis 2001, 38:1376-1380.
28. Sharma K., Ziyadeh F.N., Alzahabi B., McGowan T.A., Kapoor S., Kurnik B.R., et al. Increased renal production of transforming growth factor-beta1 in patients with type II diabetes. Diabetes 1997, 46:854-859.
29. Hellmich B., Schellner M., Schatz H., Pfeiffer A. Activation of transforming growth factor-beta1 in diabetic kidney disease. Metabolism 2000, 49:353-359.
30. Sato H., Iwano M., Akai Y., Kurioka H., Kubo A., Yamaguchi T., et al. Increased excretion of urinary transforming growth factor beta 1 in patients with diabetic nephropathy. Am J Nephrol 1998, 18:490-494.
31. Bertoluci M.C., Uebel D., Schmidt A., Thomazelli F.C., Oliveira F.R., Schmid H. Urinary TGF-beta1 reduction related to a decrease of systolic blood pressure in patients with type 2 diabetes and clinical diabetic nephropathy. Diabetes Res Clin Pract 2006, 72:258-264.
32. Morii T., Fujita H., Narita T., Shimotomai T., Fujishima H., Yoshioka N., et al. Association of monocyte chemoattractant protein-1 with renal tubular damage in diabetic nephropathy. J Diabet Complications 2003, 17:11-15.
33. Camilla R., Brachemi S., Pichette V., Cartier P., Laforest-Renald A., MacRae T., et al. Urinary monocyte chemotactic protein 1: marker of renal function decline in diabetic and nondiabetic proteinuric renal disease. J Nephrol 2011, 24:60-67.
34. Tashiro K., Koyanagi I., Saitoh A., Shimizu A., Shike T., Ishiguro C., et al. Urinary levels of monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8), and renal injuries in patients with type 2 diabetic nephropathy. J Clin Lab Anal 2002, 16:1-4.
35. Tam F.W., Riser B.L., Meeran K., Rambow J., Pusey C.D., Frankel A.H. Urinary monocyte chemoattractant protein-1 (MCP-1) and connective tissue growth factor (CCN2) as prognostic markers for progression of diabetic nephropathy. Cytokine 2009, 47:37-42.
36. Zhang X., Nagaraja H.N., Nadasdy T., Song H., McKinley A., Prosek J., et al. A composite urine biomarker reflects interstitial inflammation in lupus nephritis kidney biopsies. Kidney Int 2012, 81:401-406.
37. Lu A., Miao M., Schoeb T.R., Agarwal A., Murphy-Ullrich J.E. Blockade of TSP1-dependent TGF-beta activity reduces renal injury and proteinuria in a murine model of diabetic nephropathy. Am J Pathol 2011, 178:2573-2586.
38. Zoja C., Corna D., Benedetti G., Morigi M., Donadelli R., Guglielmotti A., et al. Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease. Kidney Int 1998, 53:726-734.
39. Ble A., Mosca M., Di Loreto G., Guglielmotti A., Biondi G., Bombardieri S., et al. Antiproteinuric effect of chemokine C-C motif ligand 2 inhibition in subjects with acute proliferative lupus nephritis. Am J Nephrol 2011, 34:367-372.
40. Nielsen S.E., Schjoedt K.J., Astrup A.S., Tarnow L., Lajer M., Hansen P.R., et al. Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Kidney Injury Molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril. Diabet Med 2010, 27:1144-1150.
41. Adler A.I., Stevens R.J., Manley S.E., Bilous R.W., Cull C.A., Holman R.R., et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003, 63:225-232.